Duchenne Kids Show Dramatic Improvement After Microdystrophin Treatment
A couple of weeks ago when I visited Solid Bio, they showed me some videos of Duchenne kids pre and post microdystrophin treatment that I was amazed by - but they weren't sharable yet. Bo just presented them at Needham this week. So cool. https://t.co/VB7ag7ole9
Pancreatic Cancer Trials Yield Only 1‑2 Month Gains
I remember years ago in pancreatic cancer trials you were realistically looking for 1 to 2 months improvement in survival (at best) in pancreatic cancer trials. Bravo $RVMD.👏
Biotech IPOs Open as Hemab Goes Public
Biotech IPO gates are opening. Congrats also to @JMaraganore (Chair) and Benny Sorensen (CEO) of Hemab, and best of luck.
Live CEO Interviews From Raymond James Biotech Symposium
Programming note: On Tuesday of next week I'll be broadcasting @BiotechTV interviews from the Raymond James Biotech Symposium in New York. Current confirmed CEO interviews: $SEPN $AKBA $WVE $VERA $DYN $KRRO (and maybe more). Let me know any questions for...
Biotech IPO Surge Expected; List on NYSE
Getting to know the @NYSE and Johanna and Eric has been a highlight of mine since their earliest support of BiotechTV. I have no doubt we will see a strong IPO pipeline for biotech this year, and I hope you...
Little‑Known Kymera Fact Worth Sharing Today
With Kymera in the news today, reposting this cool little known fact about them that I learned on a prior visit. https://t.co/ctlvveAlJZ
Prediction Markets Could Overtake Biotech Stocks for Phase‑3 Bets
I think that one day soon that prediction markets are going to replace biotech stocks for how investors play key readouts...especially wrt larger companies. For example, if Novartis has a big phase 3, isn't it more interesting and efficient to...
Tubulis Secures $5B Gilead Acquisition After CEO Vision
Last year I visited @Tubulis_GmbH in Munich, Germany. Here's what CEO Dominik Schumacher told me they were aiming to do. Congrats on today's acquisition by @gilead for up to $5B, and congrats to @schroederthilo who raved to me about this...
Merging VYKAT Reduces Market Pressure, Improves Product Outlook
When a stock becomes a circus, it can have real world impact on a product. VYKAT’s profile isn’t going to be different at the end of the day, but it will be better off as part larger company where stock...
BiotechTV Live Interviews at MassBio State of Possible
Pretty sweet setup for BiotechTv interviews at @MassBio State of Possible Conference today. If you are here, please stop by and say hello.👋 https://t.co/CQtXLi36Qk
Social Listening Remains Rare Yet Essential Communication Skill
Being aware of and caring about what people are saying about your company on social media is still a rare thing today, yet should be a bare minimum communication skill (when done appropriately). @bocumbo knows. The full interview: https://t.co/sCRPBAd8oI https://t.co/XKQQLg6STQ
CEO Amy Burroughs Discusses M&A Post‑ASH25 Data
I asked $TERN CEO Amy Burroughs right after the #ASH25 data was out how she felt about M&A. Congrats to her and her team. https://t.co/2HemPoiqWO
Pre‑Check Lets You Skip Dawn TSA Crowds
I was at Logan at 4:30AM this morning. Already there were hundreds of people in the regular TSA line. There were only dozens of people in pre-check. And, humblebrag, I have pre-check touchless and was able to walk in front...
Short‑form News with Insider Commentary Drives BiotechTV's Future
I love this video. It takes today’s news, and augments it with inside commentary straight from the newsmaker. All in a short form format that works on all platforms. This is the direction I want @BiotechTV to look more like...
Moderna Won’t Risk a Public Jury Verdict Today
If you were Moderna, would you have gambled going in front of a jury made up of the general public these days? I don’t think so.
